-
Mashup Score: 0Early PSA response among Black and non-Black patients with advanced prostate cancer treated with apalutamide - 2 year(s) ago
Future Oncology recently published an article exploring prostate health following the administration of the medication apalutamide in a real-world urology practice setting.
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
When diagnosed early, melanoma is far easier to treat and timely treatment saves lives, check out this guide to find out more.
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Melanoma rates are increasing. The good news is that nearly 9 out of 10 cases of #melanoma are preventable. Healthcare providers can make a huge difference because, when diagnosed early, melanoma is far easier to treat. Find out more >>> https://t.co/XqFdfAAsQR @focusonmelanoma
-
-
Mashup Score: 1Early PSA response among Black and non-Black patients with advanced prostate cancer treated with apalutamide - 2 year(s) ago
Future Oncology recently published an article exploring prostate health following the administration of the medication apalutamide in a real-world urology practice setting.
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Future Oncology, (@FutureOncol_FSG ) our partner journal, has recently published a Short Communication article exploring prostate health following the administration of the medication apalutamide. Find out more here >>> https://t.co/c4YHqyPbZT #ProstateCancer #PCAM
-
-
Mashup Score: 3
When diagnosed early, melanoma is far easier to treat and timely treatment saves lives, check out this guide to find out more.
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Our latest opinion piece explores the risk factors for #melanoma and provides a handy guide for clinicians to help advise their patients on how to assess suspicious moles https://t.co/XZ6TCeYw8s @focusonmelanoma
-
-
Mashup Score: 0Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas - 2 year(s) ago
Here we describe the rationale for, and design of, a clinical study of BI 764532 in patients with small cell lung cancer and other tumors containing DLL3.
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@fsgfon has recently published this #OpenAccess article discussing the Phase I trial of BI 764532 in DLL3-positive small cell lung cancer and neuroendocrine carcinomas #ClinicalTrials. Read the article here >>> https://t.co/AuEjtc9me3
-
-
Mashup Score: 0How could the STAMPEDE trial shape prostate cancer care? - 2 year(s) ago
In this video interview, filmed at the ESMO 2022 Congress (9–13 September, Paris, France), we speak with Marc Stapley – CEO of Veracyte (CA, USA) and Elai Davicioni Ph.D. – Urology Medical Director of Veracyte about exciting developments in genomic tests. We also explore the STAMPEDE trial, which aims to provide evidence as to what […]
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
What are the potential clinical implications of the #STAMPEDE trial for #prostatecancer patients? Our latest video interview explores the trial as well as advancements in genomic tests >>> https://t.co/OvUxK1QqWm @Veracayte
-
-
Mashup Score: 0Early PSA response among Black and non-Black patients with advanced prostate cancer treated with apalutamide - 2 year(s) ago
Future Oncology recently published an article exploring prostate health following the administration of the medication apalutamide in a real-world urology practice setting.
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Discover the effect of apalutamide on PSA response in Black and non-Black patients in this article from @FutureOncol_FSG >>> https://t.co/nFJpKxFPSR #ProstateCancer #PCAM
-
-
Mashup Score: 0UK’s NICE approves routine use of Ibrance®(palbociclib) to treat advanced breast cancer - 2 year(s) ago
NICE recently published draft guidance recommending a new combination treatment, palbociclib with fulvestrant, to be made available to 2,400 NHS patients.
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Recently published draft guidance from NICE recommends a new combination therapy, Ibrance® with fulvestrant, for routine use on the NHS. Take a look at the impact of this guidance on @OncologyCentral >>> https://t.co/goAhDxzp7W
-
-
Mashup Score: 0How could the STAMPEDE trial shape prostate cancer care? - 2 year(s) ago
In this video interview, filmed at the ESMO 2022 Congress (9–13 September, Paris, France), we speak with Marc Stapley – CEO of Veracyte (CA, USA) and Elai Davicioni Ph.D. – Urology Medical Director of Veracyte about exciting developments in genomic tests. We also explore the STAMPEDE trial, which aims to provide evidence as to what […]
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
How can we expand the use of #genomic tests worldwide? Find out in our latest interview with @Veracayte https://t.co/Agoo1ZQZWi
-
-
Mashup Score: 0UK’s NICE approves routine use of Ibrance®(palbociclib) to treat advanced breast cancer - 2 year(s) ago
NICE recently published draft guidance recommending a new combination treatment, palbociclib with fulvestrant, to be made available to 2,400 NHS patients.
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ibrance® (palbociclib) with fulvestrant now recommended for routine use in patients with advanced #breastcancer by UK’s NICE. Catch the latest updates via @OncologyCentral >>>https://t.co/IHm49uMlsx
-
Find out about real-world PSA responses between Black and non-Black patients initiating apalutamide for advanced prostate cancer @FutureOncol_FSG https://t.co/7VFxmIKqpZ #ProstateCancer #PCAM